Document is current
Any future updates will be listed below
-
Authors
Gomez, Jason
Fonjungo, Fonette
Chen, Stella X.
Aleshin, Maria A.
Naik, Haley B.
Wadhera, Akhil
Sayed, Christopher J.
Barnes, Leandra A.
- License Information
-
More Information
Article History
Accepted: 12 August 2024
First Online: 13 September 2024
Declarations
:
: J.G., F.F., S.X.C, and A.W. declare that they have no competing interests. M.A. has received research funding from U.C.B and consulting fees from Santa Ana Bio and Novartis. H.B.N. has received consulting fees from Abbvie, Aristea Therapeutics, Novartis, Nimbus Therapeutics, UCB, Medscape, 23andme, Sonoma therapeutics, DAVA Oncology, and Boehringer Ingelheim; serves as Vice President of the Hidradenitis Suppurativa Foundation; owns stock with Radera, Inc.; serves as Associate Editor of JAMA Dermatology. C.J.S. has served as an investigator for AbbVie, Chemocentryx, Incyte, InflaRx, Novartis, and UCB Pharma; received consulting fees from AbbVie, Alumis, InflaRx, Incyte, Logical Images, Astrazeneca, Sonoma Biotherapeutics, Novartis, and UCB Pharma, served as a speaker for AbbVie and Novartis; serves as a Board Member and Secretary of the Hidradenitis Suppurativa Foundation and Member of the European Hidradenitis Suppurativa Foundation. L.A.B. serves as an Impact Committee Subgroup Chair (unpaid) for the Hidradenitis Suppurativa Foundation.
: All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
